Group 1 - The core event was a major investment promotion activity in Liuyang, Hunan, where 15 significant projects were signed, with a total investment exceeding 6.5 billion yuan, covering various industries such as biomedicine, intelligent equipment, new materials, green food, and cultural tourism [1][2] - New Leading Pharmaceutical (Zhongshan) Co., Ltd. plans to invest 1.5 billion yuan in Liuyang, expecting an annual output value of 2 billion yuan and tax contributions of approximately 250 million yuan upon reaching full production [2] - Liuyang has introduced 78 projects with a planned investment of 23.5 billion yuan this year, including one project over 10 billion yuan and five projects over 1 billion yuan [2][3] Group 2 - Liuyang has developed a "3421" industrial tier system, which includes three pillar industries (electronic information, biomedicine, and fireworks), four advantageous industries (intelligent equipment manufacturing, new energy and automotive parts, green food, and home building materials), and two emerging industries (new materials and cultural tourism) [3] - The city has introduced over 220 billion yuan in projects through fund (capital) investment, with current annual output value exceeding 26 billion yuan, indicating a strong trend in capital-driven industrial upgrades [5] - Liuyang aims to create a favorable business environment characterized by good treatment of enterprises, excellent service experience, and strong legal protection, enhancing its attractiveness for investment [5]

Core Viewpoint - Hohhot Economic and Technological Development Zone is accelerating the layout of the biopharmaceutical industry, aiming to create a high-quality development environment and attract more biopharmaceutical enterprises to settle in the region [1][4] Group 1: Project Developments - The transdermal patch production project by Hegao Pharmaceutical Co., Ltd. and the intelligent manufacturing factory project by Xiling Biological Technology Co., Ltd. have simultaneously commenced construction [1] - The total investment for the two projects in the Yangtze River Delta and Inner Mongolia is 270 million yuan, focusing on transdermal drug delivery technology innovation and recombinant humanized active ingredient research [2] Group 2: Policy and Support - Hohhot City has introduced several policies to support high-quality development in the biopharmaceutical sector, including measures to build a strong technological city and support synthetic biology [1][4] - The development zone provides "one-stop" services in areas such as site selection, funding, project application, and technological support to facilitate project implementation [1][2] Group 3: Industry Ecosystem - The biopharmaceutical industry in Hohhot has formed a robust ecosystem, with 22 biopharmaceutical companies currently operating in the development zone, accounting for one-third of the city's total [3] - Key players in the industry include Jin Yu Biotechnology Co., Ltd. for biological vaccines, Fufeng Group Co., Ltd. and Qilu Pharmaceutical Group Co., Ltd. for biological fermentation, and Inner Mongolia Shuangqi Pharmaceutical Co., Ltd. for biopharmaceuticals [3] Group 4: Future Outlook - The industrial output value of the biopharmaceutical sector in Hohhot is projected to reach 11.09 billion yuan in 2024, with a year-on-year growth of 2% [4] - The development zone plans to enhance its industrial ecosystem, attract more high-quality biopharmaceutical enterprises, and strengthen policy support and service guarantees to promote innovation and integration of industry, academia, and research [4]